Header Logo

Connection

Michael Silverberg to Anti-Retroviral Agents

This is a "connection" page, showing publications Michael Silverberg has written about Anti-Retroviral Agents.
Connection Strength

3.174
  1. Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status. AIDS Patient Care STDS. 2015 Jul; 29(7):370-8.
    View in: PubMed
    Score: 0.496
  2. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS. 2014 Jan; 9(1):34-40.
    View in: PubMed
    Score: 0.451
  3. Do antiretrovirals reduce the risk of non-AIDS-defining malignancies? Curr Opin HIV AIDS. 2009 Jan; 4(1):42-51.
    View in: PubMed
    Score: 0.319
  4. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007 Sep 12; 21(14):1957-63.
    View in: PubMed
    Score: 0.291
  5. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007 Sep; 19(5):446-51.
    View in: PubMed
    Score: 0.290
  6. Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US. JAMA. 2023 01 03; 329(1):52-62.
    View in: PubMed
    Score: 0.210
  7. Changes in Days of Unhealthy Alcohol Use and Antiretroviral Therapy Adherence, HIV RNA Levels, and Condomless Sex: A Secondary Analysis of Clinical Trial Data. AIDS Behav. 2020 Jun; 24(6):1784-1792.
    View in: PubMed
    Score: 0.176
  8. Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. J Acquir Immune Defic Syndr. 2016 Dec 15; 73(5):540-546.
    View in: PubMed
    Score: 0.138
  9. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):160-6.
    View in: PubMed
    Score: 0.113
  10. Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009. PLoS One. 2013; 8(11):e78952.
    View in: PubMed
    Score: 0.112
  11. Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr. 2013 Mar 01; 62(3):356-62.
    View in: PubMed
    Score: 0.106
  12. Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2012 Dec; 28(12):1630-6.
    View in: PubMed
    Score: 0.100
  13. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010 Jul 17; 24(11):1765-70.
    View in: PubMed
    Score: 0.089
  14. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med. 2009 Sep; 24(9):1065-72.
    View in: PubMed
    Score: 0.083
  15. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009 Apr 30; 360(18):1815-26.
    View in: PubMed
    Score: 0.081
  16. Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study. Lancet HIV. 2022 03; 9 Suppl 1:S2.
    View in: PubMed
    Score: 0.050
  17. Cervical cancer risk in women living with HIV across four continents: A multicohort study. Int J Cancer. 2020 02 01; 146(3):601-609.
    View in: PubMed
    Score: 0.041
  18. Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. Clin Infect Dis. 2014 Apr; 58(8):1185-9.
    View in: PubMed
    Score: 0.028

© 2024 Kaiser Permanente